Silexion Therapeutics* (NASDAQ: SLXN) is making strides in oncology with its RNAi-based treatment, SIL-204, targeting KRAS-driven cancers. In an interview on Market Leaders, CEO Ilan Hadar discussed the company’s recent…
Posts published in “Market Leaders”
This Article Contains Promotional Content on behalf of Beyond Oil. Beyond Oil* (CSE: BOIL) (OTCQB: BEOLF), an innovative food-tech company, announced a transformative 5 year distribution agreement with Latitude with…